Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00AKQ
|
||||
| Former ID |
DNCL002811
|
||||
| Drug Name |
O-desulfated heparin
|
||||
| Synonyms |
Intravenous
|
||||
| Indication | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] | Phase 2 | [1] | ||
| Company |
ParinGenix
|
||||
| Target and Pathway | |||||
| Target(s) | Antithrombin-III | Target Info | Modulator | [2] | |
| KEGG Pathway | Complement and coagulation cascades | ||||
| PANTHER Pathway | Blood coagulation | ||||
| Pathway Interaction Database | Glypican 1 network | ||||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Formation of Fibrin Clot (Clotting Cascade) | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01461915) Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane. U.S. National Institutes ofHealth. | ||||
| REF 2 | Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.